NCT07019363View on ClinicalTrials.gov

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

1,903

Participants

Timeline

Start Date

June 15, 2025

Primary Completion Date

May 15, 2029

Study Completion Date

April 15, 2033

Conditions
Breast CancerAdjuvant Therapy
Interventions
DRUG

Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)

Standard endocrine therapy

DRUG

Standard endocrine therapy combined with CDK4/6 Inhibitor

CDK4/6 inhibitor therapy for 2 years in combination with standard endocrine therapy

All Listed Sponsors
lead

Fudan University

OTHER